CA2278152A1 - Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate - Google Patents
Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate Download PDFInfo
- Publication number
- CA2278152A1 CA2278152A1 CA002278152A CA2278152A CA2278152A1 CA 2278152 A1 CA2278152 A1 CA 2278152A1 CA 002278152 A CA002278152 A CA 002278152A CA 2278152 A CA2278152 A CA 2278152A CA 2278152 A1 CA2278152 A1 CA 2278152A1
- Authority
- CA
- Canada
- Prior art keywords
- methotrexate
- disease
- autoimmune
- bystander
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US60/036,722 | 1997-01-24 | ||
PCT/US1998/001648 WO1998032451A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2278152A1 true CA2278152A1 (fr) | 1998-07-30 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002278152A Abandoned CA2278152A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (fr) |
JP (1) | JP2001511134A (fr) |
KR (1) | KR20000070460A (fr) |
AU (1) | AU6648898A (fr) |
BR (1) | BR9807112A (fr) |
CA (1) | CA2278152A1 (fr) |
HU (1) | HUP0001960A2 (fr) |
IL (1) | IL131025A0 (fr) |
NO (1) | NO993600L (fr) |
WO (1) | WO1998032451A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2314182T3 (es) | 2002-02-11 | 2009-03-16 | Antares Pharma, Inc. | Inyector intradermico. |
EP1850892B2 (fr) | 2005-01-24 | 2023-04-19 | Antares Pharma, Inc. | Injecteur a seringue preremplie assiste d'une aiguille |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2007131013A1 (fr) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injecteur de reconstitution à deux étages |
WO2009114542A1 (fr) | 2008-03-10 | 2009-09-17 | Antares Pharma, Inc. | Dispositif de sécurité pour injecteur |
EP2318075B1 (fr) | 2008-08-05 | 2019-05-22 | Antares Pharma, Inc. | Injecteur à dosage multiple |
EP2408493A1 (fr) | 2009-03-20 | 2012-01-25 | Antares Pharma, Inc. | Système d'injection d'agents dangereux |
WO2011159821A1 (fr) | 2010-06-16 | 2011-12-22 | Bruce Chandler May | Utilisation de la lévocétirizine et du montélukast dans le traitement de la grippe, du rhume et d'une inflammation |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
PT2822618T (pt) | 2012-03-06 | 2024-03-04 | Antares Pharma Inc | Seringa pré-cheia com característica de força de rutura |
JP6457383B2 (ja) | 2012-04-06 | 2019-01-23 | アンタレス・ファーマ・インコーポレーテッド | テストステロン組成物の針支援式ジェット注入投与 |
WO2013169804A1 (fr) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Dispositif d'injection par jet assisté par une aiguille, présentant une force de déclenchement réduite |
ES2763633T3 (es) | 2013-02-11 | 2020-05-29 | Antares Pharma Inc | Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida |
ES2742046T3 (es) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Inyector de dosis con sistema de piñón |
WO2014165136A1 (fr) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Seringues pré-remplies à volume constant et leurs trousses |
CA2901421A1 (fr) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes |
KR20150135339A (ko) | 2013-03-13 | 2015-12-02 | 인플래머토리 리스폰스 리서치, 아이엔씨. | 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도 |
EP2968309A4 (fr) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite |
WO2016044095A1 (fr) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666080B1 (fr) * | 1987-06-24 | 2004-01-21 | Brigham & Women's Hospital | Traitement de maladies auto-immunitaires par administration orale d'auto-antigènes |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
JPH05507501A (ja) * | 1990-09-06 | 1993-10-28 | リックスウーニーベルシテイト・テ・ウットレヒト | リンパ球応答と免疫関連疾患との阻害剤 |
EP0627933B1 (fr) * | 1992-02-28 | 2002-11-27 | Autoimmune, Inc. | Suppression de maladies auto-immunes par des antigenes en attente |
WO1996040235A1 (fr) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t |
US6010722A (en) * | 1995-06-13 | 2000-01-04 | Nippon Meat Packers, Inc. | Oral remedy for rheumatoid arthritis and functional food |
-
1998
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 CA CA002278152A patent/CA2278152A1/fr not_active Abandoned
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/fr not_active Application Discontinuation
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/fr not_active Withdrawn
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Also Published As
Publication number | Publication date |
---|---|
BR9807112A (pt) | 2001-09-18 |
KR20000070460A (ko) | 2000-11-25 |
AU6648898A (en) | 1998-08-18 |
NO993600L (no) | 1999-09-23 |
EP0994717A1 (fr) | 2000-04-26 |
NO993600D0 (no) | 1999-07-23 |
HUP0001960A2 (hu) | 2000-10-28 |
JP2001511134A (ja) | 2001-08-07 |
WO1998032451A1 (fr) | 1998-07-30 |
EP0994717A4 (fr) | 2000-07-26 |
IL131025A0 (en) | 2001-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2278152A1 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
US5935577A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
AU720695B2 (en) | Bystander suppression of autoimmune diseases | |
WO1998032451A9 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
US6645504B1 (en) | Bystander suppression of type I diabetes by oral administration of glucagon | |
Daniel et al. | Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). | |
EP0506785A1 (fr) | Traitement ameliore de maladies auto-immunes par administration par aerosol d'auto-antigenes | |
Krause et al. | Immunomodulation of experimental autoimmune diseases via oral tolerance | |
AU695883B2 (en) | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines | |
AU686797B2 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
US20010007758A1 (en) | Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines | |
WO2001089557A2 (fr) | Methodes de prevention des accidents vasculaires cerebraux moyennant l'induction d'une tolerance a e-selectin | |
Virella et al. | Organ-specific autoimmune diseases | |
US20040115217A1 (en) | Bystander suppression of autoimmune diseases | |
JP2001502306A (ja) | インシュリン依存性糖尿病の処置方法および組成物 | |
Benson | Efficacy and mechanisms of oral tolerance to myelin basic protein in relapsing experimental autoimmune encephalomyelitis | |
Daniel | Analysis of insulin-specific T cells in the pathogenesis of autoimmune diabetes | |
JP2003512435A (ja) | 予防及び治療方法 | |
HAFLER et al. | I. OVERVIEW OF HUMAN AUTOIMMUNE DISEASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |